DOI QR코드

DOI QR Code

Further Study on Pemetrexed based chemotherapy in Treating Patients with Advanced Gastric Cancer (AGC)

  • Liu, Jin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Feng, Ji-Feng (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
  • Published : 2014.08.30

Abstract

Objective: To further observe the efficacy and safety of pemetrexed, combined with Irinotecan or oxaliplatin or cisplatin in treating patients with advanced gastric cancer as second-line or third-line chemotherapy. Methods: From September 2013 to February 2014 we recruited 50 patients with advanced gastric cancer, with stage IV disease or postoperative recurrence, or unresectable. Then treated with pemetrexed based chemotherapy. After two cycles of treatment, efficacy and toxicity were evaluated. Results: Pemetrexed based chemotherapy was used as second-line in 33 patients, RR(CR+PR) is 41.2%. And achieved 36.4% when used as third-line. Overall response rate of 50 patients treated with Pemetrexed based treatment was 38% (CR+PR). Treatment related side effects were bone marrow suppression, vomiting, hepatic dysfunction and malaise.No treatment related death occurred. Conclusions: Treatment with pemetrexed based chemotherapy is active and is well tolerated in patients with advanced gastric cancer.

Keywords

Pemetrexed based chemotherapy;advanced gastric cancer (AGC);efficacy and safety

References

  1. Bajetta E, Celio L, Buzzoni R et al (2003). Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol, 14, 1543-8. https://doi.org/10.1093/annonc/mdg406
  2. Calvert H (1999). An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Semi Oncol, 26, 3-10.
  3. Celio L, Buzzoni R, Longarini R, Marchiano A, Bajetta E (2002). Pemetrexed in gastric cancer: clinical experience and future perspectives. Semin Oncol, 29, 63-8. https://doi.org/10.1053/sonc.2002.37475
  4. Guo-Li Wei1, Xin-En Huang et al (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6. https://doi.org/10.7314/APJCP.2013.14.5.2703
  5. Kim YH, Chung HC, Kang WK, et al (2008). Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. Cancer Chemother Pharmacol, 62, 263-70. https://doi.org/10.1007/s00280-007-0600-y
  6. Kuo YC, Liu HT, Lin YL (2014). Modified biweekly oxaliplatin and capecitabine for advanced gastric cancer: a retrospective analysis from a medical center. Biomed J, 37, 141-6.
  7. Liu J, Huang XE, Tian GY, et al (2013). Phase II Study on Safety and Efficacy of $Yadanzi^{(R)}$ (Javanica oil emulsion injection) Combined with Chemotherapy for Patients with Gastric Cancer. Asian Pac J Cancer Prev, 14, 2009-12. https://doi.org/10.7314/APJCP.2013.14.3.2009
  8. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. https://doi.org/10.7314/APJCP.2013.14.4.2663
  9. Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8. https://doi.org/10.7314/APJCP.2013.14.3.2005
  10. Parkin DM, Bray F et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  11. Sato T, Tomaru K, Koide T, et al (2012). Synchronous lung and gastric cancers successfully treated with carboplatin and pemetrexed: a case report. J Med Case Rep, 6, 266. https://doi.org/10.1186/1752-1947-6-266
  12. Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403. https://doi.org/10.7314/APJCP.2012.13.5.2399
  13. Rino Y, Yukawa N1, Sato T, et al (2013). Phase II study on the combination of irinotecan plus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer. Mol Clin Oncol, 1, 749-52.
  14. Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22. https://doi.org/10.7314/APJCP.2013.14.3.2019
  15. Xu X, Wang L, Xu HQ, et al (2013). Clinical comparison between paclitaxel liposome ($Lipusu^{(R)}$) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev, 14, 2591-4. https://doi.org/10.7314/APJCP.2013.14.4.2591
  16. Zhan YP, Huang XE, Cao J (2012). Clinical safety and efficacy of $Kanglaite^{(R)}$ (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 5319-21. https://doi.org/10.7314/APJCP.2012.13.10.5319

Cited by

  1. Clinical Study of Nimotuzumab Combined with Chemotherapy in the Treatment of Late Stage Gastric Cancer vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10273
  2. Clinical Study on Safety and Efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection Manufactured in China) for Chinese Undergoing Chemotherapy vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.299
  3. Effects of Analgecine on Oxaliplatin-Induced Neurotoxicity in Patients with Gastrointestinal Cancer vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4465
  4. Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4791
  5. RASAL1 Attenuates Gastric Carcinogenesis in Nude Mice by Blocking RAS/ERK Signaling vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1077
  6. Survival Effect of Supportive Care Services for Turkish Patients with Metastatic Gastric Cancer vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1213
  7. Peroxisome Proliferator-Activated Receptor-Gamma Pro12Ala Polymorphism Could be a Risk Factor for Gastric Cancer vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2333
  8. Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance Status vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2355
  9. Pemetrexed in Treating Patients with Metastatic Bladder Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3839
  10. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3867
  11. Clinical Observation on Recombinant Human Endostatin Combined with Chemotherapy for Advanced Gastrointestinal Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4037
  12. Clinical Application of Serum Tumor Abnormal Protein from Patients with Gastric Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4041
  13. Coenzyme Complex Decreased Cardiotoxicity When Combined with Chemotherapy in Treating Elderly Patients with Gastrointestinal Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4045
  14. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
  15. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485
  16. Evaluation of METase-pemetrexed-loaded PEG–PLGA nanoparticles modified with anti-CD133–scFV for treatment of gastric carcinoma vol.38, pp.1, 2017, https://doi.org/10.1042/BSR20171001